Drug Profile


Alternative Names: Aquavan Injection; Fospropofol disodium; GPI 15715; HX0507; Lusedra; PQ 1002

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MGI GP
  • Developer Eisai Co Ltd; Yichang Humanwell Pharmaceutical
  • Class Anaesthetics; Hypnosedatives; Phenols; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sedation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Sedation(In volunteers) in China (IV, Injection)
  • 16 Nov 2009 Launched for Sedation in USA (IV)
  • 14 Dec 2008 Registered for Sedation in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top